Article Text

Download PDFPDF
Novel ADAMTSL4 gene mutations in Chinese patients with isolated ectopia lentis
  1. Dongwei Guo,
  2. Fengmei Yang,
  3. Yijing Zhou,
  4. Xinyu Zhang,
  5. Qianzhong Cao,
  6. Guangming Jin,
  7. Danying Zheng
  1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China
  1. Correspondence to Dr Guangming Jin, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China; jingm{at}mail2.sysu.edu.cn; Dr Danying Zheng, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China; zhengdyy{at}163.com

Abstract

Background To characterise the phenotype and genetic defects of isolated ectopia lentis (IEL) and to determine the ADAMTSL4 gene mutation frequencies in a Chinese congenital ectopia lentis (CEL) cohort.

Methods In total, 127 Chinese probands with a clinical CEL diagnosis were recruited for this study and underwent ocular and systemic examinations. Whole-exome sequencing was used to detect variants, and Sanger sequencing and bioinformatics analysis verified the pathogenic mutations.

Results Overall, biallelic mutations in ADAMTSL4, involving 8 novel ADAMTSL4 mutations (c.21–2A>G, c.1174G>C, c.2169C>A, c.2236C>T, c.2263delG, c.2397C>A, c.2488dupC and c.2935T>C) were identified in 5 probands (5/127, 3.94%) with IEL. Additionally, four patients had combined congenital cataracts, and two patients had ectopia lentis et pupillae (ELP). One of eight mutations was a homozygous missense mutation, and the other seven mutations were compound heterozygous. These eight consisted of three missense (37.5%), three frameshift (37.5%), one stop-gain (12.5%) and one spicing mutation (12.5%). These mutations co-segregated with the IEL, and the substitution of amino acids greatly affected conserved residues. Most of the novel mutations were located in the thrombospondin type 1 (TSP1) domain, which ultimately alters the structure of the ADAMTSL4 protein.

Conclusions This study reported five IEL probands with eight novel mutations in the ADAMTSL4 gene. The clinical IEL phenotypes caused by these mutations were variable and complex. This study thus establishes the ADAMTSL4 gene mutation frequency and expands the gene’s mutation spectrum to help recognise ADAMTSL4-related IEL clinical manifestations.

  • lens and zonules
  • genetics

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information. Not applicable.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information. Not applicable.

View Full Text

Footnotes

  • DG and FY are joint first authors.

  • GJ and DZ contributed equally.

  • Correction notice This paper has been updated since it was first published. A funding statement has been added.

  • Contributors DZ and GJ designed the study. DG and FY collected the data and wrote the manuscript. YZ, QC and XZ provided critical review for the manuscript. DZ is responsible for the overall content as the guarantor.

  • Funding This work was supported by National Natural Science Foundation of China (81873673, 81900841) and the Guangdong Basic and Applied Basic Research Foundation (2021A1515011673).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Linked Articles

  • Highlights from this issue
    Frank Larkin